Status: Recruiting
Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma
This is a single-arm, phase II study that is designed to investigate nodal and primary tumor CTV dose de-escalation (30 Gy) in HPV positive oropharyngeal cancer.
Participants needed: 31
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sara MedekUpdated: May 18, 2026Locations: 1
Eligibility criteria
Patients must have histologically or cytologically confirmed history of squamous... [+8]
1. Patients with metastatic or recurrent disease.